KIT mutation
|
Thymic Carcinoma
|
KIT mutation
|
Thymic Carcinoma
|
sunitinib Sensitive: A2 - Guideline
|
sunitinib Sensitive: A2 - Guideline
|
KIT mutation
|
Cutaneous Melanoma
|
KIT mutation
|
Cutaneous Melanoma
|
imatinib Sensitive: A2 - Guideline
|
imatinib Sensitive: A2 - Guideline
|
KIT mutation
|
GIST
|
KIT mutation
|
GIST
|
ripretinib Sensitive: B - Late Trials
|
ripretinib Sensitive: B - Late Trials
|
KIT mutation
|
GIST
|
KIT mutation
|
GIST
|
TAS-116 Sensitive: B - Late Trials
|
TAS-116 Sensitive: B - Late Trials
|
KIT mutation
|
GIST
|
KIT mutation
|
GIST
|
avapritinib Sensitive: C2 – Inclusion Criteria
|
avapritinib Sensitive: C2 – Inclusion Criteria
|
KIT mutation
|
GIST
|
KIT mutation
|
GIST
|
imatinib Sensitive: C2 – Inclusion Criteria
|
imatinib Sensitive: C2 – Inclusion Criteria
|
KIT mutation
|
Melanoma
|
KIT mutation
|
Melanoma
|
imatinib Sensitive: C2 – Inclusion Criteria
|
imatinib Sensitive: C2 – Inclusion Criteria
|
KIT mutation
|
Melanoma
|
KIT mutation
|
Melanoma
|
sunitinib Sensitive: C2 – Inclusion Criteria
|
sunitinib Sensitive: C2 – Inclusion Criteria
|
KIT mutation
|
Melanoma
|
KIT mutation
|
Melanoma
|
nivolumab Sensitive: C2 – Inclusion Criteria
|
nivolumab Sensitive: C2 – Inclusion Criteria
|
KIT mutation
|
GIST
|
KIT mutation
|
GIST
|
sunitinib + PLX9486 Sensitive: C3 – Early Trials
|
sunitinib + PLX9486 Sensitive: C3 – Early Trials
|
KIT mutation
|
AML
|
KIT mutation
|
AML
|
LY3009120 Sensitive: C3 – Early Trials
|
LY3009120 Sensitive: C3 – Early Trials
|
KIT mutation
|
Mucosal Melanoma
|
KIT mutation
|
Mucosal Melanoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
KIT mutation
|
AML
|
KIT mutation
|
AML
|
ivosidenib Resistant: C3 – Early Trials
|
ivosidenib Resistant: C3 – Early Trials
|
KIT mutation
|
Mucosal Melanoma
|
KIT mutation
|
Mucosal Melanoma
|
temozolomide Sensitive: C3 – Early Trials
|
temozolomide Sensitive: C3 – Early Trials
|
KIT mutation
|
Mucosal Melanoma
|
KIT mutation
|
Mucosal Melanoma
|
cisplatin + dacarbazine Sensitive: C3 – Early Trials
|
cisplatin + dacarbazine Sensitive: C3 – Early Trials
|
KIT mutation
|
Cutaneous Melanoma
|
KIT mutation
|
Cutaneous Melanoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
KIT mutation
|
Melanoma
|
KIT mutation
|
Melanoma
|
ripretinib Sensitive: C3 – Early Trials
|
ripretinib Sensitive: C3 – Early Trials
|
KIT mutation
|
GIST
|
KIT mutation
|
GIST
|
AZD1775 + avapritinib Sensitive: D – Preclinical
|
AZD1775 + avapritinib Sensitive: D – Preclinical
|
KIT mutation
|
AML
|
KIT mutation
|
AML
|
cabozantinib tablet Sensitive: D – Preclinical
|
cabozantinib tablet Sensitive: D – Preclinical
|